Ratings for NeoGenomics (NASDAQ:NEO) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for NeoGenomics, revealing an average target of $19.6, a high estimate of $22.00, and a low estimate of $19.00. Observing a 4.53% increase, the current average has risen from the previous average price target of $18.75.

Interpreting Analyst Ratings: A Closer Look

The analysis of recent analyst actions sheds light on the perception of NeoGenomics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of NeoGenomics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on NeoGenomics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know NeoGenomics Better

Understanding the Numbers: NeoGenomics's Finances

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: NeoGenomics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 10.44%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: NeoGenomics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -10.55%, the company may face hurdles in effective cost management.

Return on Equity (ROE): NeoGenomics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.94%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): NeoGenomics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.08%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: NeoGenomics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.67.

The Basics of Analyst Ratings

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.